The Clinical Practice Gaps in Precision Medicine
Lead the Change: Close the Practice Gaps
The healthcare ecosystem has evolved fast. But have the factors preventing patients from receiving the right treatment evolved with it?
Building on the globally recognised 2022 study
Four years ago, our first Clinical Practice Gaps Analysis revealed a headline that shook the industry:
64.4%
of patients aren’t receiving the best treatment for them
Downloaded 31,000+ times, the report has since became a reference point across pharma and diagnostic communities. Now, we’re releasing Part 2, a fresh, data driven analysis looking at how the seven practice gaps have evolved and where patients are still being lost. Haven’t read the first paper? It’s a must read foundation.
Are we closing the gaps… or widening them?
Pharma, lab and industry leaders all asked us one question more than any other after the first Clinical Practice Gaps Analysis: “Is the 64% number getting better?”
Over the past four years, the precision medicine ecosystem has expanded rapidly - with broader biomarker panels, increased therapeutic options, wider NGS adoption, and more frequent guideline updates. Our new Clinical Practice Gaps Analysis – Part 2 gives a four year update on the seven gaps identified in the original report downloaded by 31,000+ clinicians, industry leaders, and pharma partners worldwide.
Discover
- How patient loss has shifted across the seven practice gaps
- Where guideline-discordant decisions persist
- What steps we can take today to close the practice gaps
The new data tells a story that every stakeholder should understand. If you’re shaping strategy, diagnostics, or commercialization plans these insights matter.
Did the system improve or did the gaps simply shiftDownload paper
